{"component": "definition", "props": {"groups": [{"samples": [{"hash": "5gLkWXiXZxq", "uri": "/contracts/5gLkWXiXZxq#client-product", "label": "Cell Line License Agreement (InMed Pharmaceuticals Inc.)", "score": 37.6872005476, "published": true}, {"hash": "9sJW5bIpXex", "uri": "/contracts/9sJW5bIpXex#client-product", "label": "Cell Line License Agreement (Cyclerion Therapeutics, Inc.)", "score": 37.4353179932, "published": true}, {"hash": "88mBI3Z5b15", "uri": "/contracts/88mBI3Z5b15#client-product", "label": "Cell Line License Agreement (Glycomimetics Inc)", "score": 36.2553062439, "published": true}], "snippet_links": [{"key": "to-licensee", "type": "definition", "offset": [28, 39]}, {"key": "by-the-licensee", "type": "clause", "offset": [61, 76]}, {"key": "licensed-cell-line", "type": "definition", "offset": [99, 117]}, {"key": "amendment-to-this-agreement", "type": "clause", "offset": [215, 242]}, {"key": "new-client", "type": "definition", "offset": [264, 274]}], "size": 14, "snippet": "means the [***] of interest to Licensee, which is designated by the Licensee to be produced by the Licensed Cell Line. Each different Client Product covered under this Agreement shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell Line.", "hash": "02a392b0421a280136655a4489eae20c", "id": 1}, {"samples": [{"hash": "feQCfZichJl", "uri": "/contracts/feQCfZichJl#client-product", "label": "Aol Online Services Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}, {"hash": "eLecFXXCP6I", "uri": "/contracts/eLecFXXCP6I#client-product", "label": "Stockholders' Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}, {"hash": "aynBGy353VP", "uri": "/contracts/aynBGy353VP#client-product", "label": "Stockholders' Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "aol-license", "type": "definition", "offset": [40, 51]}], "size": 5, "snippet": "shall have the meaning set forth in the AOL License.", "hash": "fa126b0aa2e08df44eac5c3384675724", "id": 2}, {"samples": [{"hash": "eLecFXXCP6I", "uri": "/contracts/eLecFXXCP6I#client-product", "label": "Stockholders' Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}, {"hash": "c2H9QXBtBQN", "uri": "/contracts/c2H9QXBtBQN#client-product", "label": "Aol License Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}, {"hash": "aynBGy353VP", "uri": "/contracts/aynBGy353VP#client-product", "label": "Stockholders' Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "licensed-products", "type": "clause", "offset": [28, 45]}, {"key": "operating-systems", "type": "clause", "offset": [75, 92]}, {"key": "an-individual", "type": "clause", "offset": [107, 120]}, {"key": "the-functions", "type": "definition", "offset": [144, 157]}, {"key": "by-the-client", "type": "clause", "offset": [167, 180]}, {"key": "exchange-of-information", "type": "clause", "offset": [247, 270]}, {"key": "server-product", "type": "definition", "offset": [280, 294]}], "size": 5, "snippet": "means each component of the Licensed Products that executes on one or more operating systems being used by an individual end- user. Examples of the functions provided by the Client Product include Audiovisual Presentations to the end-user and the exchange of information with the Server Product.", "hash": "568800cedf018cfbb8722928ba4ae3f2", "id": 3}, {"samples": [{"hash": "bA36yIdr1KE", "uri": "/contracts/bA36yIdr1KE#client-product", "label": "Commercial Fill/Finish Services Agreement (Avedro Inc)", "score": 30.0458583832, "published": true}, {"hash": "3AID0XaSyvR", "uri": "/contracts/3AID0XaSyvR#client-product", "label": "Commercial Fill/Finish Services Agreement (Avedro Inc)", "score": 29.9691982269, "published": true}, {"hash": "l6W2DtAf0VS", "uri": "/contracts/l6W2DtAf0VS#client-product", "label": "Commercial Fill/Finish Services Agreement (Avedro Inc)", "score": 29.8815879822, "published": true}], "snippet_links": [{"key": "finished-dosage-form", "type": "definition", "offset": [64, 84]}, {"key": "this-agreement", "type": "clause", "offset": [91, 105]}, {"key": "appendix-b", "type": "definition", "offset": [123, 133]}, {"key": "mutual-agreement-of-the-parties", "type": "clause", "offset": [175, 206]}, {"key": "from-time-to-time", "type": "clause", "offset": [207, 224]}, {"key": "during-the-term", "type": "clause", "offset": [225, 240]}], "size": 3, "snippet": "means the pharmaceutical product(s) to be Produced by \u2587\u2587\u2587\u2587\u2587\u2587 in finished dosage form under this Agreement as identified on Appendix B hereto, which Appendix may be updated by mutual agreement of the parties from time to time during the Term..", "hash": "f7563aeecdff7800a575ac7957ee67e8", "id": 4}, {"samples": [{"hash": "WwKE9AT5D0", "uri": "/contracts/WwKE9AT5D0#client-product", "label": "Master Product Development and Clinical Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "1Skd0RcfcKp", "uri": "/contracts/1Skd0RcfcKp#client-product", "label": "Master Product Development and Clinical Supply Agreement (Alder Biopharmaceuticals Inc)", "score": 25.3285427094, "published": true}], "snippet_links": [{"key": "this-agreement", "type": "clause", "offset": [108, 122]}, {"key": "to-the-client", "type": "clause", "offset": [148, 161]}, {"key": "the-context", "type": "clause", "offset": [206, 217]}, {"key": "the-term", "type": "clause", "offset": [228, 236]}, {"key": "of-client", "type": "clause", "offset": [284, 293]}, {"key": "certain-confidential-information", "type": "clause", "offset": [404, 436]}, {"key": "contained-in", "type": "definition", "offset": [437, 449]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [499, 537]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [538, 554]}, {"key": "securities-act-of-1933", "type": "definition", "offset": [569, 591]}, {"key": "as-amended", "type": "definition", "offset": [593, 603]}, {"key": "bulk-drug-substance", "type": "definition", "offset": [615, 634]}, {"key": "drug-product", "type": "definition", "offset": [636, 648]}, {"key": "finished-product", "type": "clause", "offset": [657, 673]}, {"key": "or-modifications", "type": "clause", "offset": [732, 748]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [769, 795]}, {"key": "other-client", "type": "definition", "offset": [1029, 1041]}, {"key": "services-for", "type": "clause", "offset": [1086, 1098]}, {"key": "for-client", "type": "definition", "offset": [1125, 1135]}, {"key": "by-a-third-party", "type": "clause", "offset": [1136, 1152]}, {"key": "the-pre", "type": "clause", "offset": [1206, 1213]}, {"key": "existing-agreement", "type": "clause", "offset": [1214, 1232]}, {"key": "section-152", "type": "clause", "offset": [1247, 1259]}, {"key": "project-plan", "type": "definition", "offset": [1277, 1289]}, {"key": "between-the-parties", "type": "clause", "offset": [1312, 1331]}], "size": 3, "snippet": "or \u201cProduct\u201d shall mean the proprietary biological pharmaceutical product(s) to be Produced by \u2587\u2587\u2587\u2587\u2587\u2587 under this Agreement, and refers specifically to the Client Product identified in the related PWA. When the context requires, the term \u201cClient Product\u201d also means the tangible forms of Client Product which are or are to be Produced by \u2587\u2587\u2587\u2587\u2587\u2587 under this Agreement, \u2587\u2587\u2587\u2587\u2587\u2587 & ALDER CONFIDENTIAL 2 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. including Bulk Drug Substance, Drug Product, and/or Finished Product, and also including all in-process intermediates, samples or modifications thereof or thereto. For the avoidance of doubt, \u201cClient Product\u201d under this Agreement is limited to Bulk Drug Substance Produced under this Agreement, Drug Product Produced from such Bulk Drug Substance, and/or Finished Product Produced from such Bulk Drug Substance, and for any other Client product(s) or production (e.g., fill-finish services for drug product manufactured for Client by a third party), such product(s) or production shall be governed by the pre-existing agreement referenced in Section 15.2 and the related \u201cProject Plan\u201d (as defined therein) between the parties.", "hash": "0db5349ba56718163ab9220ea59e8426", "id": 5}, {"samples": [{"hash": "5UxrGK33SFU", "uri": "/contracts/5UxrGK33SFU#client-product", "label": "Master Services Agreement (GT Biopharma, Inc.)", "score": 31.7624912262, "published": true}, {"hash": "iAlJyA9s0Tk", "uri": "http://pdf.secdatabase.com/435/0001654954-20-010920.pdf", "label": "pdf.secdatabase.com", "score": 10.8754281998, "published": false}], "snippet_links": [{"key": "drug-substance", "type": "definition", "offset": [20, 34]}, {"key": "drug-product", "type": "definition", "offset": [36, 48]}, {"key": "for-client", "type": "definition", "offset": [81, 91]}, {"key": "performance-of-services", "type": "definition", "offset": [112, 135]}], "size": 2, "snippet": "means the RCB, MCB, Drug Substance, Drug Product or other TriKE Product produced for Client by Cytovance during performance of Services.", "hash": "046d74bda751711453b152cafe330f37", "id": 6}, {"samples": [{"hash": "bHTrirOngob", "uri": "/contracts/bHTrirOngob#client-product", "label": "Commercial Supply Agreement (Acelrx Pharmaceuticals Inc)", "score": 32.622177124, "published": true}, {"hash": "1QVP5ZYkkjc", "uri": "https://ir.acelrx.com/static-files/d091fe4e-8788-4fb8-bedc-f3bcf62416a9", "label": "ir.acelrx.com", "score": 10.811088562, "published": false}], "snippet_links": [{"key": "single-dose", "type": "definition", "offset": [17, 28]}, {"key": "drug-product", "type": "definition", "offset": [63, 75]}, {"key": "quality-agreement", "type": "definition", "offset": [144, 161]}], "size": 2, "snippet": "means a packaged single dose applicator (\u201cSDA\u201d) containing the Drug Product, as more fully and specifically described in the Specifications and Quality Agreement.", "hash": "dbe14319cd5ea4af0ad88c739e0f5e98", "id": 7}, {"samples": [{"hash": "iMwLeCgGlW1", "uri": "/contracts/iMwLeCgGlW1#client-product", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "iIk04LOtDuJ", "uri": "/contracts/iIk04LOtDuJ#client-product", "label": "License Agreement (Versartis, Inc.)", "score": 29.585899353, "published": true}], "snippet_links": [{"key": "diagnostic-product", "type": "definition", "offset": [37, 55]}, {"key": "the-msa", "type": "definition", "offset": [112, 119]}], "size": 2, "snippet": "means a preventative, therapeutic or diagnostic product incorporating the recombinant proteins designated under the MSA.", "hash": "38a8dc020621acfcfcec76b68cf80d68", "id": 8}, {"samples": [{"hash": "cQH3RZILysY", "uri": "/contracts/cQH3RZILysY#client-product", "label": "Master Manufacturing Services Agreement (Versartis, Inc.)", "score": 29.6433944702, "published": true}, {"hash": "6yN7NdL59dJ", "uri": "/contracts/6yN7NdL59dJ#client-product", "label": "Master Manufacturing Services Agreement (Versartis, Inc.)", "score": 29.585899353, "published": true}], "snippet_links": [{"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [7, 41]}, {"key": "biological-product", "type": "definition", "offset": [80, 98]}], "size": 2, "snippet": "shall, for the purposes of this Agreement only, mean any Client investigational biological product that uses Biologic Manufactured and supplied hereunder for therapeutic purposes.", "hash": "0571c0201bd4917c1676d971564f5010", "id": 9}, {"samples": [{"hash": "eLecFXXCP6I", "uri": "/contracts/eLecFXXCP6I#client-product", "label": "Stockholders' Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}, {"hash": "aynBGy353VP", "uri": "/contracts/aynBGy353VP#client-product", "label": "Stockholders' Agreement (America Online Latin America Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "cis-license", "type": "definition", "offset": [40, 51]}], "size": 2, "snippet": "shall have the meaning set forth in the CIS License.", "hash": "16d7787a970061fa4a7847cb32154b02", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXY2xpZW50LXByb2R1Y3QjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Client Product", "size": 60, "snippet": "means the [***] of interest to Licensee, which is designated by the Licensee to be produced by the Licensed Cell Line. Each different Client Product covered under this Agreement shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell Line.", "id": "client-product", "examples": ["Notwithstanding the foregoing, the existence of this Agreement and its non-technical terms may be disclosed confidentially in connection with a potential financing, collaboration or acquisition or in discussion with a potential acquirer of <strong>Client Product</strong>.", "WuXi Biologics will provide assistance to Licensee, and any sublicensee, in respect of Licensee\u2019s or such sublicensee\u2019s regulatory filing activities for the <strong>Client Product</strong> and/or Drug Product, at Licensee\u2019s or such sublicensee\u2019s reasonable cost and expense on [***] rate.", "Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used the Licensed Cell Line for any purpose other than as provided hereunder, including operating the Process, the manufacture of <strong>Client Product</strong>, Drug Substance and Drug Product, and for other purposes reasonably related to securing Marketing Authorization Approval for the <strong>Client Product</strong> and/or Drug Product.", "WuXi Biologics will provide [***] assistance to enable such Third Party Manufacturer to manufacture <strong>Client Product</strong>, provided, however, it is the Third Party Manufacturer\u2019s full responsibility to manufacture such <strong>Client Product</strong> after the transfer, WuXi Biologics will not be responsible for the Third Party Manufacturer\u2019s success or failure to manufacture any <strong>Client Products</strong>.", "As consideration for the license granted in Section 2 of this Agreement, and the representation and warranty set forth in Section 10 of this Agreement, Licensee agrees to pay WuXi Biologics a fixed non-creditable, non-refundable license fee of USD 150,000 for the Licensed Cell Line used in <strong>Client Product</strong>."], "related": [["product", "Product", "Product"], ["hemp-product", "Hemp product", "Hemp product"], ["finished-product", "Finished Product", "Finished Product"], ["non-microsoft-product", "Non-Microsoft Product", "Non-Microsoft Product"], ["bundled-product", "Bundled Product", "Bundled Product"]], "related_snippets": [], "updated": "2026-09-11T08:21:27+00:00"}, "json": true, "cursor": ""}}